Scholarlink

<p>High-dose dexamethasone (HDD) is widely used as first-line therapy for immune thrombocytopenia (ITP) and is administered at a fixed dose regardless of body weight. The impact of body mass index (BMI) on treatment response to HDD remains unclear. This retrospective, two-center study included 60 adult patients with newly diagnosed ITP who received HDD as first-line therapy. Demographic characteristics, BMI, baseline laboratory values, and treatment responses at&#xa0;1, 6, and 12&#xa0;months were analyzed. BMI was evaluated using cut-off values of 25, 27, and 30. The median number of HDD cycles administered was 1 (range: 1–4), and the median BMI at diagnosis was 27.0&#xa0;kg/m<sup>2</sup> (range: 18.0–44.0). No significant differences were observed between BMI categories with regard to treatment responses at months 1 and 6 (<i>p</i> &gt; 0.05 for both). However, at month 12, a complete response (CR) was more likely in patients with BMI &lt; 30, and a partial response (PR) in those with BMI ≥ 30 (<i>p</i> = 0.023). Across all time points, no other demographic or clinical variable emerged as an independent predictor of treatment response (<i>p</i> &gt; 0.05). The results of this study indicate that in newly diagnosed ITP patients receiving HDD as first-line treatment, BMI does not influence early or durable treatment responses, although it may have a modest adverse effect on late response. Larger prospective studies are needed to clarify underlying mechanisms and assess whether obesity-related factors should inform individualized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of body mass index on treatment response to high-dose dexamethasone in adult primary immune thrombocytopenia patients: A two-center retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Abdulkerim Yıldız,
  • Rafiye Çiftçiler,
  • Samet Yaman,
  • Minura Abishova Aliyeva,
  • Sedat Acar,
  • Shabnam Shahab,
  • Huriye Baysal

摘要

High-dose dexamethasone (HDD) is widely used as first-line therapy for immune thrombocytopenia (ITP) and is administered at a fixed dose regardless of body weight. The impact of body mass index (BMI) on treatment response to HDD remains unclear. This retrospective, two-center study included 60 adult patients with newly diagnosed ITP who received HDD as first-line therapy. Demographic characteristics, BMI, baseline laboratory values, and treatment responses at 1, 6, and 12 months were analyzed. BMI was evaluated using cut-off values of 25, 27, and 30. The median number of HDD cycles administered was 1 (range: 1–4), and the median BMI at diagnosis was 27.0 kg/m2 (range: 18.0–44.0). No significant differences were observed between BMI categories with regard to treatment responses at months 1 and 6 (p > 0.05 for both). However, at month 12, a complete response (CR) was more likely in patients with BMI < 30, and a partial response (PR) in those with BMI ≥ 30 (p = 0.023). Across all time points, no other demographic or clinical variable emerged as an independent predictor of treatment response (p > 0.05). The results of this study indicate that in newly diagnosed ITP patients receiving HDD as first-line treatment, BMI does not influence early or durable treatment responses, although it may have a modest adverse effect on late response. Larger prospective studies are needed to clarify underlying mechanisms and assess whether obesity-related factors should inform individualized treatment.